DPTIP | Neutral sphingomyelinase 2 inhibitor
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $80.00 | ||
| 25 mg | $290.00 |
DPTIP (351353-48-5) is a selective, potent (IC50 = 30 nM), and brain penetrant inhibitor of neutral sphingomyelinase 2 (nSMase2).1 I In a mouse model of brain injury, it inhibited IL-1ß-induced astrocyte-derived extracellular vesicle release which reduced cytokine upregulation and attenuation of infiltration of immune cells to the brain leading to decreased inflammation. DPTIP displayed potent antiviral activity against Zika and West Nile viruses (EC50 Vero cells: 0.26 µM and 1.56 µM respectively).2 DPTIP acted synergistically with enzalutamide to significantly suppress cell proliferation, colony formation, and migration of metastatic castration resistant prostate cancer cells.3 It also reduced tumor size and weight in a prostate cancer mouse model.
References/Citations:
- Rojas et al. (2018), DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation; Sci. Rep. 8 17715
- Alvarez-Fernandez et al. (2022); Allosteric Inhibition of Neutral Sphingomyelinase 2 (nSMase2) by DPTIP: From Antiflaviviral Activity to Deciphering Its Binding Site through In Silico Studies and Experimental Validation, Int. J. Mol. Sci., 23 13935
- Shams et al. (2024), Blockade of neutral sphingomyelinase 2 exerts antitumor effect on metastatic castration resistant prostate cancer cells and promotes tumor regression when combined with Enzalutamide; Am. J. Cancer Res. 14 5697
C21H18N2O3S
>98% HPLC
NMR: (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
DPTIP (351353-48-5) is a selective, potent (IC50 = 30 nM), and brain penetrant inhibitor of neutral sphingomyelinase 2 (nSMase2).1 I In a mouse model of brain injury, it inhibited IL-1ß-induced astrocyte-derived extracellular vesicle release which reduced cytokine upregulation and attenuation of infiltration of immune cells to the brain leading to decreased inflammation. DPTIP displayed potent antiviral activity against Zika and West Nile viruses (EC50 Vero cells: 0.26 µM and 1.56 µM respectively).2 DPTIP acted synergistically with enzalutamide to significantly suppress cell proliferation, colony formation, and migration of metastatic castration resistant prostate cancer cells.3 It also reduced tumor size and weight in a prostate cancer mouse model.
References/Citations:
- Rojas et al. (2018), DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation; Sci. Rep. 8 17715
- Alvarez-Fernandez et al. (2022); Allosteric Inhibition of Neutral Sphingomyelinase 2 (nSMase2) by DPTIP: From Antiflaviviral Activity to Deciphering Its Binding Site through In Silico Studies and Experimental Validation, Int. J. Mol. Sci., 23 13935
- Shams et al. (2024), Blockade of neutral sphingomyelinase 2 exerts antitumor effect on metastatic castration resistant prostate cancer cells and promotes tumor regression when combined with Enzalutamide; Am. J. Cancer Res. 14 5697
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
Focus Biomolecules • Plymouth Meeting, PA USA • 1-855-FOCUS21
Focus Biomolecules
Plymouth Meeting, PA USA
1-855-FOCUS21
Website Created by Advanta Advertising LLC.